Vitality Watch

Dossier pubmed review 28-oct-2026
Narrative review or expert overview without new data

Beyond reproduction: the emerging role of FSH in postmenopausal aging.

Key claim: Postmenopausal elevation of follicle-stimulating hormone (FSH) may actively drive bone loss, visceral adiposity, cardiometabolic dysfunction, and cognitive decline, representing both a systemic risk biomarker and a viable therapeutic target.

Abstract

Follicle-stimulating hormone (FSH) is traditionally regarded as a biochemical marker of menopause and declining ovarian function. However, emerging evidence suggests that its role may extend beyond reproductive physiology. During the menopause transition, FSH concentrations rise progressively, initially due to declining inhibin B and later to loss of ovarian estradiol and inhibin production. Evidence of FSH effects in bone, adipose tissue, the cardiovascular system and brain has raised the possibility of broader physiological actions. Higher FSH levels have been associated with bone loss and hip fracture risk, adverse cardiometabolic and vascular changes, and cognitive decline and Alzheimer’s disease. Although these associations do not establish causality, they suggest that FSH may contribute to some consequences of reproductive aging rather than simply reflect ovarian failure. Experimental studies indicate that reducing FSH may benefit bone and adiposity, while preliminary clinical evidence regarding cognition remains inconclusive. Thus, FSH may represent not only a marker of menopause, but also a potential marker of risk and, ultimately, a therapeutic target.

Why this matters

This review [expert-opinion] broadens the menopause–systemic aging framework from loss of estrogen signaling to a possible additional contribution from elevated FSH across skeletal, metabolic, cardiovascular, and cognitive domains. The proposed biomarker and therapeutic roles remain distinct from demonstrated human risk-prediction utility or treatment benefit; the synthesis does not establish that lowering FSH prevents postmenopausal decline.

Source

Link

Briefing card

Beyond reproduction: the emerging role of FSH in postmenopausal aging.
Stage: review · pubmed · 28-oct-2026

Postmenopausal elevation of follicle-stimulating hormone (FSH) may actively drive bone loss, visceral adiposity, cardiometabolic dysfunction, and cognitive decline, representing both a systemic risk biomarker and a viable therapeutic target.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1080/09513590.2026.2752665

build build 880 · 2bcef25 · 2026-11-18